Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity

Chaoqi Liu1, Jiao Lu1, Huiqun Tian1

  • 1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei 443001, P.R. China.

Insights

Human papillomavirus (HPV) E7 protein drives cervical cancer immune evasion by increasing PD-L1 expression, leading to T cell dysfunction. Restoring T cell activity may involve inhibiting the PD-L1/PD-1 pathway.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Cytotoxic T lymphocyte (CTL) dysfunction, often linked to PD-L1/PD-1 pathway activation, presents a major challenge in cancer therapy.
  • Human papillomavirus (HPV) infection is a primary cause of cervical cancer and can contribute to immune evasion.

Purpose of the Study:

  • To investigate the mechanisms by which HPV-induced cervical cancer cells evade the host immune system via the PD-L1/PD-1 signaling pathway.
  • To explore the potential of targeting the PD-L1/PD-1 pathway for cervical cancer immunotherapy.

Main Methods:

  • Comparative analysis of HPV16E7 and PD-L1 expression in cervical tissues using immunohistochemistry and RT-PCR.
  • In vitro studies involving overexpression and knockdown of HPV16E7 in cancer cell lines (PC3, CaSki).
  • Assessment of peripheral blood mononuclear cell (PBMC) proliferation and CTL activity.
  • Transfection of CaSki cells with a soluble PD-1 expressing plasmid and co-culture with PBMCs.

Main Results:

  • Significantly elevated HPV16E7 and PD-L1 expression in cervical cancer tissues compared to normal tissues, with a positive correlation between them.
  • Overexpression of HPV16E7 increased PD-L1 levels, inhibiting PBMC proliferation and CTL activity.
  • HPV16E7 knockdown reduced PD-L1 expression and enhanced PBMC proliferation and CTL activity.
  • Soluble PD-1 treatment significantly increased PBMC proliferation and CTL activity.

Conclusions:

  • HPV16E7-induced PD-L1 overexpression contributes to lymphocyte dysfunction in cervical cancer.
  • Inhibiting the PD-L1/PD-1 pathway, potentially with soluble PD-1, can restore tumor-infiltrating lymphocyte function.
  • These findings offer novel insights for developing immunotherapeutic strategies against cervical cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K